Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®

This is a phase 2, open-label clinical trial determining feasibility, safety, and tolerability of GammaTile® in elderly or frail subjects with newly diagnosed or recurrent malignant gliomas.

Inclusion Criteria: * Supratentorial * A bi-dimensionally measurable lesion of at least 10 mm, visible on two or more axial slices 5 mm apart. * The pre-operative tumor planned for resection is ≤ 7 cm in maximal dimension. * Tumor, which in the opinion of the enrolling neurosurgeon, is amenable to attempted gross total resection (GTR) or near total resection (NTR). * Anticipated GT placement (i.e., closest aspect of post resection tumor bed anticipated to receive GT placement) that is \> 15mm from the optic chiasm or brainstem. * If multifocal, must be fully resectable in one operative bed. Surgical protocol will follow current institutional standards. * Able to receive 5-aminolevulinic acid (5-ALA, Gleolan) or other institutionally standard immunofluorescent-guidance such as fluorescein, prior to surgery to optimize GTR or NTR of enhancing tumor. * Karnofsky Performance Scale (KPS) 1. Elderly GBM: baseline KPS score of ≥ 60. 2. Frail GBM: baseline (pre-GBM diagnosis) is \